X

Trial Profile

A phase 1 monotherapy trial of ADG116 in patients with advanced/metastatic solid tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 14 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ADG 116 (Primary)
Indications Solid tumours
Focus Therapeutic Use
Sponsors Adagene

Most Recent Events

07 Nov 2024 According to an Adagene media release, data from this trial will be presented in a poster at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, taking place in Houston, Nov. 6 - 10, 2024.
30 Aug 2022 According to an Adagene media release, advanced dose escalation to 10 mg/kg in the trial is ongoing.
31 Mar 2022 According to an Adagene media release, initiated dose escalation in this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com